Business
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer SymposiumUpdated data analysis continues to show that Narmafotinib combination compares favourably with gemcitabine and Abraxane combination alone Melbourne, Australia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that interim data from the ongoing ACCENT tr
About this update from Amplia Therapeutics Ltd.
[{"type":"text","content":"HIGHLIGHTS","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer Symposium","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated data analysis continues to show that Narmafotinib combination compares favourably with gemcitabine and Abraxane combination alone ","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":284,"olType":false},{"type":"text","content":"Melbourne, Australia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that interim data from the ongoing ACCENT trial in metastatic pancreatic cancer was showcased in a poster presentation on Friday 9 January (US time) at the American Society for Clinical Oncology: Gastrointestinal Cancer Symposium (ASCO GI) by Chief Medical Officer, Dr Jason Lickliter. The ACCENT trial is Amplia’s lead clinical program, assessing the efficacy of the company’s leading FAK inhibitor, narmafotinib, in combination with standard chemotherapy, for patients with advanced pancreatic cancer.","length":663,"tagName":"p"},{"type":"text","content":"The poster shares data that highlight both the effectiveness and safety of narmafotinib, showing promise for improving treatment results in patients with pancreatic cancer. Key points from the poster are:","length":204,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The updated progression-free survival (PFS) is 7.7 months, compared to 5.5 months for Gemcitabine and Abraxane alone1","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"The overall response rate (ORR) is 35%; this increases to 42% when including unconfirmed responses","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Narmafotinib continues to be well tolerated by patients with the adverse effect profile of the narmafotinib – chemotherapy combination similar to chemotherapy alone","length":164,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":379,"olType":false},{"type":"text","content":"A copy of the poster is available on the Company website.","length":57,"tagName":"p"},{"type":"text","content":"Dr Chris Burns, CEO of Amplia, commented, &...